At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 31 enrolled
Drug / intervention
Levodopa-carbidopa intestinal gel +3 moredrug
Likely dose
Levodopa-carbidopa intestinal gel 10 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication
In Brief
A Phase 3 clinical trial evaluating Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, and 2 other interventions for Advanced Parkinson's Disease. Completed, enrolled 31 participants.
Detailed Summary
The primary objective of this study is to measure the efficacy of ABT-SLV187 in subjects with advanced Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Parkinson's Disease
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionMar 2015
TodayJul 2026
First PostedOct 11, 2013
Enrollment StartOct 1, 2013
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.7 years ago
Interventions
Levodopa-carbidopa intestinal geldrug
Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
CADD-Legacy® 1400 ambulatory infusion pumpdevice
PEG tubedevice
percutaneous endoscopic gastrostomy tube
J-tubedevice
jejunal tube